Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro

Neuropharmacology

Volumn 56, Issue 2, 2009, Pages 422-428

  Crespo Biel, N ^a,b   Camins, A ^a,b   Pallas M ^a,b   Canudas, A M ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

3 Nitropropionic acid; Calcium; Calpain; Lithium; Neurodegenerative disease; p35; Spectrin

Indexed keywords

3 NITROPROPIONIC ACID; ACTIN; CALCIUM; CALPAIN; CYCLIN DEPENDENT KINASE 5; LITHIUM; MYOCYTE ENHANCER FACTOR 2; PROTEIN P35;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; CALCIUM; CALPAIN; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUNTINGTON DISEASE; LITHIUM CHLORIDE; MALE; MICE; NEURONS; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SUCCINATE DEHYDROGENASE;

EID: 58549093742     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.09.012     Document Type: Article

References (50)

1. Akashiba H., Ikegaya Y., Nishiyama N., and Matsuki N. Differential involvement of cell cycle reactivation between striatal and cortical neurons in cell death induced by 3-nitropropionic acid. Journal of Biological Chemistry 283 (2008) 6594-6606
2. Alvarez G., Muñoz-Montaño J.R., Satrústegui J., Avila J., Bogónez E., and Díaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disorders 4 (2002) 153-165 Review
3. Arlinghaus L., Mehdi S., and Lee K.S. Improved posthypoxic recovery with a membrane-permeable calpain inhibitor. European Journal of Pharmacology 209 (1991) 123-125
4. 2+ exchanger in excitotoxicity. Cell 120 (2005) 275-285
5. Beal F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histological characterization of striatal excitotoxic lesions produced by mitochondrial toxin 3-nitropropionic acid. Journal of Neuroscience 13 (1993) 4181-4192
6. Beal M.F. Mitochondria and neurodegeneration. Novartis Foundation Symposium 287 (2007) 183-192 discussion 192-196. Review
7. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., and Lee C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proceedings of the National Academy of Sciences USA 97 (2000) 11074-11079
8. Bizat N., Hermel J.M., Boyer F., Jacquard C., Créminon C., Ouary S., Escartin C., Hantraye P., Kajewski S., and Brouillet E. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. Journal of Neuroscience 23 (2003) 5020-5030
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 (1976) 248-254
10. Brouillet E., Condé F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Progress in Neurobiology 59 (1999) 427-468 Review
11. Calabrese V., Scapagnini G., Giuffrida Stella A.M., Bates T.E., and Clark J.B. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochemical Research 26 (2001) 739-764 Review
12. Camins A., Verdaguer E., Folch J., Canudas A.M., and Pallàs M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspective 19 (2006) 453-460
13. Centeno F., Mora A., Fuentes J.M., Soler G., and Claro E. Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons. Neuroreport 9 (1998) 4199-4203
14. Chalecka-Franaszek E., and Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proceedings of the National Academy of Sciences USA 96 (1999) 8745-8750
15. Chen R.W., and Chuang D.W. Long term lithium treatment suppresses p53 and bax expression but increases Bcl-2 expression. Journal of Biological Chemistry 274 (1999) 6039-6042
16. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., and Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. Journal of Neurochemistry 72 (1999) 879-882
17. Crespo-Biel N., Camins A., Pelegrí C., Vilaplana J., Pallàs M., and Canudas A.M. 3- nitropropionic acid activates calpain/cdk5 pathway in rat striatum. Neuroscience Letters 421 (2007) 77-81
18. Crocker S.J., Smith P.D., Jackson-Lewis V., Lamba W.R., Hayley S.P., Grimm E., Callaghan S.M., Slack R.S., Melloni E., Przedborski S., Robertson G.S., Anisman H., Merali Z., and Park D.S. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. Journal of Neuroscience 23 (2003) 4081-4091
19. Di Rosa G., Odrijin T., Nixon R.A., and Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. Journal of Molecular Neuroscience 19 (2002) 135-141
20. Emerson C.P. Myogenesis and developmental control genes. Current Opinion in Cell Biology 2 (1990) 1065-1075
21. Franceschini D., Giusti P., and Skaper S.D. MEK inhibition exacerbates ischemic calcium imbalance and neuronal cell death in rat cortical cultures. European Journal of Pharmacology 553 (2006) 18-27
22. 2+ overload induced by a mitochondrial toxin, 3-nitropropionic acid. Neuroscience 87 (1998) 497-507
23. Gafni J., and Ellerby L.M. Calpain activation in Huntington's disease. Journal of Neuroscience 22 (2002) 4842-4849
24. Galas M.C., Bizat N., Cuvelier L., Bantubungi K., Brouillet E., Schiffmann S.N., and Blum D. Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiology of Disease 15 (2004) 152-159
25. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., and Chuang D.M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. Journal of Neurochemistry 80 (2002) 589-597
26. Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara S., and Saido T.C. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. Journal of Biological Chemistry 280 (2005) 15229-15237
27. Inouye M., Yamamura H., and Nakano A. Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. Journal of Radiation Research 36 (1995) 203-208
28. Jordà E.G., Verdaguer E., Morano A., Jiménez A., Canudas A.M., Camins A., and Pallàs M. Lithium prevents colchicine-induced apoptosis in rat cerebellar granule neurons. Bipolar Disorders 6 (2004) 144-149
29. Jordà E.G., Verdaguer E., Canudas A.M., Jiménez A., Garcia de Arriba S., Allgaier C., Pallàs M., and Camins A. Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 134 (2005) 1001-1011
30. Lee K.S., Frank S., Vanderklish P., Arai A., and Lynch G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proceedings of the National Academy of Sciences USA 88 (1991) 7233-7237
31. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., and Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405 (2000) 360-364
32. Lee W.T., Itoh T., and Pleasure D. Acute and chronic alterations in calcium homeostasis in 3-nitropropionic acid-treated human NT2-N neurons. Neuroscience 113 (2002) 699-708
33. Li X., Bijur G.N., and Jope R.S. Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disorders 4 (2002) 137-144
34. Manji H.K., McNamara R., Chen G., and Lenox R.H. Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness. Australian and New Zealand Journal of Psychiatry 33 Suppl. (1999) S65-S83 Review
35. Manji H.K., Moore G.J., and Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?. Biological Psychiatry 46 (1999) 929-940 Review
36. Mora A., Sabio G., González-Polo R.A., Cuenda A., Alessi D.R., Alonso J.C., Fuentes J.M., Soler G., and Centeno F. Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. Journal of Neurochemistry 78 (2001) 199-206
37. Mora A., Sabio G., Alonso J.C., Soler G., and Centeno F. Different dependence of lithium and valproate on PI3K/PKB pathway. Bipolar Disorders 4 (2002) 195-200
38. 2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid. Neurochemistry International 43 (2003) 89-99
39. Nonaka S., and Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9 (1998) 2081-2084
40. Oliveira J.M., Jekabsons M.B., Chen S., Lin A., Rego A.C., Gonçalves J., Ellerby L.M., and Nicholls D.G. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. Journal of Neurochemistry 101 (2007) 241-249
41. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., and Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999) 615-622
42. Saito K., Elce J.S., Hamos J.E., and Nixon R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proceedings of the National Academy of Sciences USA 90 (1993) 2628-2632
43. Schmued L.C., and Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Research 874 (2000) 123-130
44. Shaldubina A., Agam G., and Belmaker R.H. The mechanism of lithium action: state of the art, ten years later. Progress in Neuro-Psychopharmacology and Biological Psychiatry 25 (2001) 855-866 Review
45. Shao L., Young L.T., and Wang J.F. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biological Psychiatry 58 (2005) 879-884
46. Wei H., Qin Z.H., Senatorov V.V., Wei W., Wang Y., Qian Y., and Chuang D.M. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106 (2001) 603-612
47. Wood N.I., and Morton A.J. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Research Bulletin 61 (2003) 375-383
48. Yeste-Velasco M., Folch J., Trullàs R., Abad M.A., Enguita M., Pallàs M., and Camins A. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology 53 (2007) 295-307
49. Youdim M.B., and Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46 (2004) 1130-1140
50. Yokota M., Saido T.C., Tani E., Kawashima S., and Suzuki K. Three distinct phases of fodrin proteolysis induced in postischemic hippocampus. Involvement of calpain and unidentified protease. Stroke 26 (1995) 1901-1907